{"disease":{"id":"renal","name":"renal"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"ipilimumab","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"cabometyx","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"cabometyx","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"bevacizumab","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"tacrolimus","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"lenvatinib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"axitinib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inlyta","generic_name":"axitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mast/stem cell growth factor receptor Kit","drug_class":"Kinase Inhibitor [EPC]","quality_score":82,"revenue":"923","mechanism":"Inlyta works by blocking the activity of the mast/stem cell growth factor receptor Kit, which is involved in the growth and spread of cancer cells."},{"drug_id":"everolimus","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"belzutifan","indication_name":"Advanced Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welireg","generic_name":"BELZUTIFAN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"HIF-2α","drug_class":"Hypoxia-inducible Factor Inhibitor [EPC]","quality_score":75,"revenue":"509","mechanism":"Belzutifan inhibits HIF-2α, blocking its interaction with HIF-1β to reduce expression of genes linked to tumor growth."},{"drug_id":"avelumab","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bavencio","generic_name":"avelumab","company_name":"Merck KGaA","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":69,"revenue":"400","mechanism":"Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"darbepoetin-alfa","indication_name":"Anemia of renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aranesp","generic_name":"DARBEPOETIN ALFA","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating Agent [EPC]","quality_score":10,"revenue":"400","mechanism":"Aranesp works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production."},{"drug_id":"sorafenib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexavar","generic_name":"SORAFENIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"200","mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"inulin","indication_name":"Renal function study","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"INULIN","company_name":"Iso Tex","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"losartan-potassium","indication_name":"Diabetic renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cozaar","generic_name":"LOSARTAN POTASSIUM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker","quality_score":69,"revenue":null,"mechanism":"Cozaar works by blocking the action of angiotensin II on its receptor, which helps to relax blood vessels and lower blood pressure."},{"drug_id":"paricalcitol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zemplar","generic_name":"PARICALCITOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D2 Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Zemplar works by activating the Vitamin D3 receptor, mimicking the natural effects of Vitamin D to regulate calcium levels and bone health."},{"drug_id":"captopril","indication_name":"Diabetic renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Capozide 25/15","generic_name":"CAPTOPRIL","company_name":"Aarxion Anda Hlding","drug_phase":"marketed","molecular_target":"Renin","drug_class":"Thiazide Diuretic [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"iodamide","indication_name":"Renal arteriography","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ametriodic Acid","generic_name":"IODAMIDE","company_name":"Bracco","drug_phase":"marketed","molecular_target":"","drug_class":"iodamide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"cinacalcet","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sensipar","generic_name":"CINACALCET","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"Calcium-sensing Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood."},{"drug_id":"zirabev","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"betamethasone-acetate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"molidustat","indication_name":"Renal anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Musredo","generic_name":"MOLIDUSTAT","company_name":"BAYER YAKUHIN, Ltd","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"bavencio","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bavencio","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"acetohydroxamic-acid","indication_name":"Struvite Renal Calculi","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithostat","generic_name":"ACETOHYDROXAMIC ACID","company_name":"Mission Pharma","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Urease Inhibitor [EPC]","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"sunitinib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with normal renal function.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with impaired renal function.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting renal tubular acidosis.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"synarel","indication_name":"Exclusion of other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synarel","generic_name":"Nafarelin Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptors","drug_class":"Gonadotropin-releasing hormone agonists","quality_score":67,"revenue":null,"mechanism":"Gonadotropin-releasing hormone agonist medication"},{"drug_id":"multihance-0-1-mmol-kg","indication_name":"Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MultiHance 0.1 mmol/kg","company_name":"Bracco Diagnostics, Inc","drug_phase":"marketed","molecular_target":"Water protons in tissue; blood-brain barrier; vascular endothelium","drug_class":"Paramagnetic contrast agent; gadolinium-based MRI contrast medium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"sunitinib-malate","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunitinib Malate","generic_name":"sunitinib-malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":80,"revenue":null,"mechanism":"Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET."},{"drug_id":"aldactone","indication_name":"Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"aldactone","indication_name":"Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"tetracosactide","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortrosyn","generic_name":"tetracosactide","company_name":"Amphastar Pharms Inc","drug_phase":"marketed","molecular_target":"Melanocortin receptor 4","drug_class":"Adrenocorticotropic Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nexavar","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nexavar","company_name":"Fujian Medical University","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Cyclin-dependent kinase-like 2, Cyclin-dependent kinase-like 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pembrolizuma","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"cabozantinib","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"cabozantinib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"calciferol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"afinitor","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"imlifidase","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ides","generic_name":"IMLIFIDASE","company_name":"Hansa Biopharma AB","drug_phase":"marketed","molecular_target":"Immunoglobulin gamma (IgG), heavy chain","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"trientine","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Syprine","generic_name":"TRIENTINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 14","drug_class":"Copper Chelator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"torasemide","indication_name":"Renal Disease with Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Torasemide","company_name":"Medical University of Warsaw","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"muromonab","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Muromonab","company_name":"St. Jude Children's Research Hospital","drug_phase":"phase_2","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"yervoy","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"inlyta","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inlyta","generic_name":"Axitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3","drug_class":"Receptor tyrosine kinase inhibitor","quality_score":63,"revenue":null,"mechanism":"Axitinib inhibits VEGFR-1, VEGFR-2, and VEGFR-3 to block pathologic angiogenesis and tumor growth."},{"drug_id":"sutent","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"Sunitinib Malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET","drug_class":"Small molecule kinase inhibitor","quality_score":67,"revenue":null,"mechanism":"Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression."},{"drug_id":"aranesp","indication_name":"Anemia of renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aranesp","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"alfacalcidol","indication_name":"Renal osteodystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alfarol","generic_name":"ALFACALCIDOL","company_name":"","drug_phase":"discontinued","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"alfacalcidol","quality_score":null,"revenue":null,"mechanism":"Alfarol works by activating vitamin D receptors in the body, which helps regulate calcium levels."},{"drug_id":"methylclothiazide","indication_name":"Renal Disease with Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enduron","generic_name":"methylclothiazide","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"androstanolone","indication_name":"Anemia of chronic renal failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neodrol","generic_name":"androstanolone","company_name":"","drug_phase":"unknown","molecular_target":"Sex hormone-binding globulin","drug_class":"androstanolone","quality_score":null,"revenue":null,"mechanism":"Neodrol works by binding to androgen receptors, mimicking the effects of natural androgens like testosterone."},{"drug_id":"hydrocortisone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"phenolsulfonphthalein","indication_name":"Renal function study","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fenolipuna","generic_name":"phenolsulfonphthalein","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"phenolsulfonphthalein","quality_score":null,"revenue":null,"mechanism":"Fenolipuna works by being excreted by the kidneys, allowing for the assessment of renal function."},{"drug_id":"betiatide","indication_name":"Diagnosis of congenital and acquired renal abnormalities","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Technescan Mag3","generic_name":"BETIATIDE","company_name":"Curium","drug_phase":"marketed","molecular_target":"","drug_class":"betiatide","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"betiatide","indication_name":"Diagnosis of renal failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Technescan Mag3","generic_name":"BETIATIDE","company_name":"Curium","drug_phase":"marketed","molecular_target":"","drug_class":"betiatide","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"crinecerfont","indication_name":"classic congenital adrenal hyperplasia (CAH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crenessity","generic_name":"CRINECERFONT","company_name":"Neurocrine","drug_phase":"marketed","molecular_target":"","drug_class":"Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Crenessity blocks the hormone corticotropin-releasing factor, which stimulates the adrenal glands to produce excess hormones."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"belatacept","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nulojix","generic_name":"BELATACEPT","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"T-lymphocyte activation antigen CD80","drug_class":"Selective T Cell Costimulation Blocker [EPC]","quality_score":52,"revenue":null,"mechanism":"Nulojix blocks the activation of T cells by binding to CD80, preventing an immune response."},{"drug_id":"votrient","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Votrient","company_name":"Tracon Pharmaceuticals Inc.","drug_phase":"marketed","molecular_target":"Bone morphogenetic protein receptor type-1B, Cyclin-dependent kinase 11A, Cyclin-dependent kinase 11B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"triamcinolone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"renvela","indication_name":"Renal Osteodystrophy with Hyperphosphatemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Renvela","company_name":"Ardelyx","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"renvela","indication_name":"Renal dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Renvela","company_name":"Ardelyx","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"losartan","indication_name":"Diabetic renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cozaar","generic_name":"losartan","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"AT1 receptor","drug_class":"ARB (Angiotensin II receptor blocker)","quality_score":65,"revenue":null,"mechanism":"Losartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 receptor."},{"drug_id":"nandrolone","indication_name":"Anemia of chronic renal failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nandrolon","generic_name":"NANDROLONE","company_name":"","drug_phase":"marketed","molecular_target":"Sex hormone-binding globulin","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doxercalciferol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hectorol","generic_name":"DOXERCALCIFEROL","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D2 Analog [EPC]","quality_score":70,"revenue":null,"mechanism":"Hectorol works by activating the Vitamin D receptor, which helps regulate calcium levels in the body."},{"drug_id":"calcitriol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcijex","generic_name":"CALCITRIOL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D3 Analog [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"calcitriol","indication_name":"Hypocalcemia from End-Stage Renal Disease with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcijex","generic_name":"CALCITRIOL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D3 Analog [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"calcitriol","indication_name":"Renal osteodystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcijex","generic_name":"CALCITRIOL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D3 Analog [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"bumetanide","indication_name":"Renal Disease with Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bumex","generic_name":"BUMETANIDE","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"Loop Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"torisel","indication_name":"advanced renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Torisel","generic_name":"Temsirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1","drug_class":"temsirolimus","quality_score":10,"revenue":null,"mechanism":"Temsirolimus is an inhibitor of mTOR, a protein that controls cell division."},{"drug_id":"allopurinol","indication_name":"Calcium renal calculus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aloprim","generic_name":"ALLOPURINOL","company_name":"Casper Pharma Llc","drug_phase":"marketed","molecular_target":"Xanthine dehydrogenase/oxidase","drug_class":"Xanthine Oxidase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Aloprim works by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid in the body."},{"drug_id":"allopurinol","indication_name":"Recurrent Calcium Renal Calculi","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aloprim","generic_name":"ALLOPURINOL","company_name":"Casper Pharma Llc","drug_phase":"marketed","molecular_target":"Xanthine dehydrogenase/oxidase","drug_class":"Xanthine Oxidase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Aloprim works by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid in the body."},{"drug_id":"allopurinol","indication_name":"Uric acid renal calculus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aloprim","generic_name":"ALLOPURINOL","company_name":"Casper Pharma Llc","drug_phase":"marketed","molecular_target":"Xanthine dehydrogenase/oxidase","drug_class":"Xanthine Oxidase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Aloprim works by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid in the body."},{"drug_id":"calcifediol","indication_name":"Renal osteodystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rayaldee","generic_name":"CALCIFEDIOL","company_name":"","drug_phase":"marketed","molecular_target":"Sterol regulatory element-binding protein 1","drug_class":"calcifediol","quality_score":10,"revenue":null,"mechanism":"Rayaldee works by increasing the levels of active vitamin D in the body."},{"drug_id":"prednisone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"calcium","indication_name":"end stage renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcium Acetate","generic_name":"CALCIUM","company_name":"Fresenius Medcl Care","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Calcium Acetate works by providing supplemental calcium to the body, which is essential for various bodily functions including muscle and nerve function."},{"drug_id":"arginine","indication_name":"Renal radiation exposure from Lutetium (177Lu) oxodotreotide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"R-Gene 10","generic_name":"ARGININE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nitric oxide synthase, inducible","drug_class":"arginine hydrochloride","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mitotane","indication_name":"Carcinoma in situ of adrenal cortex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lysodren","generic_name":"MITOTANE","company_name":"Esteve","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6","drug_class":"mitotane","quality_score":70,"revenue":null,"mechanism":"Lysodren works by inhibiting the production of cortisol and aldosterone in the adrenal cortex."},{"drug_id":"methylprednisolone-acetate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"methylprednisolone-acetate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"aldesleukin","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proleukin","generic_name":"ALDESLEUKIN","company_name":"Chiron","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Lymphocyte Growth Factor [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"axitinib-ag-013736","indication_name":"Advanced renal cell carcinoma (RCC) after failure of prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axitinib (AG-013736)","generic_name":"axitinib-ag-013736","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"vascular endothelial growth factor receptors (VEGFRs)","drug_class":"tyrosine kinase inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"axitinib-ag-013736","indication_name":"Advanced renal cell carcinoma (RCC) as a first-line treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axitinib (AG-013736)","generic_name":"axitinib-ag-013736","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"vascular endothelial growth factor receptors (VEGFRs)","drug_class":"tyrosine kinase inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"penicillamine","indication_name":"Cystine Renal Calculi","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cuprimine","generic_name":"PENICILLAMINE","company_name":"Valeant Pharms Intl","drug_phase":"marketed","molecular_target":"","drug_class":"Antirheumatic Agent [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"muromonab-cd3","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orthoclone Okt3","generic_name":"MUROMONAB-CD3","company_name":"Ortho Biotech","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"CD3 Blocker Immunosuppressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"probenecid","indication_name":"Adjunct Treatment to Inhibit Renal Drug Excretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Col-Probenecid","generic_name":"probenecid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 9","drug_class":"probenecid","quality_score":10,"revenue":null,"mechanism":"ORLYNVAH combines sulopenem etzadroxil, a penem antibacterial, with probenecid to increase sulopenem's plasma concentration by inhibiting its renal clearance."},{"drug_id":"sirolimus","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rapamune","generic_name":"sirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"mTOR Inhibitor Immunosuppressant [EPC]","quality_score":80,"revenue":null,"mechanism":"Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells."},{"drug_id":"daclizumab","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zenapax","generic_name":"DACLIZUMAB","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Interleukin-2 Receptor Blocking Antibody","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"amifostine","indication_name":"Prevention of Cancer Chemotherapy-Induced Renal Impairment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ethyol","generic_name":"AMIFOSTINE","company_name":"Cosette","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"amifostine","quality_score":75,"revenue":null,"mechanism":"Ethyol works by protecting the kidneys and salivary glands from damage caused by chemotherapy and radiation."},{"drug_id":"irbesartan","indication_name":"Diabetic renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avapro","generic_name":"IRBESARTAN","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"calcium-acetate","indication_name":"Renal Osteodystrophy with Hyperphosphatemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phoslo","generic_name":"CALCIUM ACETATE","company_name":"Fresenius Medcl Care","drug_phase":"marketed","molecular_target":"","drug_class":"calcium acetate","quality_score":75,"revenue":null,"mechanism":"Phoslo works by increasing calcium levels in the blood to treat conditions related to low calcium."},{"drug_id":"metolazone","indication_name":"Renal Disease with Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zaroxolyn","generic_name":"METOLAZONE","company_name":"I3 Pharms","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 7","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"torsemide","indication_name":"Edema associated with renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TORSEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/K+/2Cl- carrier system","drug_class":"Loop Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water."},{"drug_id":"chlorthalidone","indication_name":"Edema due to renal dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTHALIDONE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/Cl− cotransporter","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cortisol","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zemplar","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zemplar","company_name":"Danderyd Hospital","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"proleukin","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Proleukin","company_name":"University of Minnesota","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"darbepoetin","indication_name":"Anemia of renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Darbepoetin","company_name":"NICHD Neonatal Research Network","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nulojix","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nulojix","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rapamycin","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamycin","company_name":"Institut National de la Santé Et de la Recherche Médicale, France","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rocaltrol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rocaltrol","company_name":"Shandong University","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rocaltrol","indication_name":"Hypocalcemia from End-Stage Renal Disease with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rocaltrol","company_name":"Shandong University","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rocaltrol","indication_name":"Renal osteodystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rocaltrol","company_name":"Shandong University","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zenapax","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zenapax","company_name":"National Institute of Neurological Disorders and Stroke (NINDS)","drug_phase":"phase_3","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"glypressin","indication_name":"Hepatorenal syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"glypressin","company_name":"Tanta University","drug_phase":"phase_1","molecular_target":"Vasopressin V1a receptor, Vasopressin V2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"alphacalcidol","indication_name":"Renal osteodystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Alphacalcidol","company_name":"University of Ioannina","drug_phase":"phase_2","molecular_target":"Sodium-dependent noradrenaline transporter, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"calcium","indication_name":"end stage renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcium Acetate","generic_name":"CALCIUM","company_name":"Fresenius Medcl Care","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Calcium Acetate works by providing supplemental calcium to the body, which is essential for various bodily functions including muscle and nerve function."},{"drug_id":"bevacizumab-maly","indication_name":"Metastatic Renal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"hyoscyamine","indication_name":"Biliary and Renal Colic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(-)-Atropine","generic_name":"Hyoscyamine","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"hyoscyamine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"torisel","indication_name":"Advanced renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Torisel","generic_name":"Temsirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1","drug_class":"temsirolimus","quality_score":10,"revenue":null,"mechanism":"Temsirolimus is an inhibitor of mTOR, a protein that controls cell division."},{"drug_id":"chlorothiazide","indication_name":"Edema in Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sunitinib","indication_name":"Advanced Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"dexamethasone-phosphate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sodium-succinate","indication_name":"Renal Diseases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM SUCCINATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"gadobenate-dimeglumine","indication_name":"MRA of Renal and Aorto-ilio-femoral Vessels","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Multihance","generic_name":"GADOBENATE DIMEGLUMINE","company_name":"Bracco","drug_phase":"marketed","molecular_target":"","drug_class":"gadobenate dimeglumine","quality_score":50,"revenue":null,"mechanism":"Multihance works by enhancing the contrast of MRI images through the paramagnetic properties of gadobenate dimeglumine."},{"drug_id":"chembl-chembl1789844","indication_name":"Advanced Renal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3833373","indication_name":"Advanced Renal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVELUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors."},{"drug_id":"calcitriol-capsules","indication_name":"Hypocalcemia in Chronic Renal Dialysis Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calcitriol capsules","company_name":"Indonesia University","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin D3 Analog [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"ethacrynic-acid","indication_name":"Edema in Renal Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"epoetin-theta","indication_name":"Anemia of chronic renal failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eporatio","generic_name":"EPOETIN THETA","company_name":"","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"simulect","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Simulect","company_name":"Astellas Pharma Inc","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor subunit alpha","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"phenosulfazole","indication_name":"Renal function study","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenolsulfon","generic_name":"phenosulfazole","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Phenosulfazole works by interacting with a specific biological target to modulate renal function."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"enarodustat","indication_name":"Anemia of renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enaroy","generic_name":"ENARODUSTAT","company_name":"Japan Tabacco","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"basiliximab","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chrft5","generic_name":"BASILIXIMAB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor subunit alpha","drug_class":"Interleukin-2 Receptor Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"daprodustat","indication_name":"Anemia of renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jesduvroq","generic_name":"DAPRODUSTAT","company_name":"GSK","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Jesduvroq works by activating hypoxia-inducible factor prolyl hydroxylase inhibitors, which increases the production of erythropoietin, a hormone that stimulates red blood cell production."},{"drug_id":"citric-acid","indication_name":"Calcium Phosphate Renal Calculi","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"CITRIC ACID","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Anti-coagulant","quality_score":50,"revenue":null,"mechanism":"Renacidin works by inhibiting the formation of calcium oxalate crystals in the urine, which can help prevent kidney stones."},{"drug_id":"citric-acid","indication_name":"Struvite Renal Calculi","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"CITRIC ACID","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Anti-coagulant","quality_score":50,"revenue":null,"mechanism":"Renacidin works by inhibiting the formation of calcium oxalate crystals in the urine, which can help prevent kidney stones."},{"drug_id":"rapamune","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamune","company_name":"Wyeth is now a wholly owned subsidiary of Pfizer","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"irbesartan-hydrochloride","indication_name":"Diabetic renal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avapro","generic_name":"IRBESARTAN HYDROCHLORIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Avapro works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"lysine","indication_name":"Renal radiation exposure from Lutetium (177Lu) oxodotreotide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"L-Lysine","generic_name":"LYSINE","company_name":"Advanced Accelerator Applications","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"lysine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"avastin","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"magnesium-carbonate","indication_name":"Calcium Phosphate Renal Calculi","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"MAGNESIUM CARBONATE","company_name":"United Guardian","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin C [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"magnesium-carbonate","indication_name":"Struvite Renal Calculi","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"MAGNESIUM CARBONATE","company_name":"United Guardian","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin C [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"sodium-phosphate-monobasic-monohydrate","indication_name":"Calcium renal calculus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Osmoprep","generic_name":"sodium phosphate, monobasic, monohydrate","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Calculi Dissolution Agent [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"sevelamer-carbonate","indication_name":"Renal Osteodystrophy with Hyperphosphatemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renvela","generic_name":"SEVELAMER CARBONATE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Phosphate Binder","quality_score":60,"revenue":null,"mechanism":"Renvela works by binding to dietary phosphate in the gut, preventing its absorption into the bloodstream."},{"drug_id":"sevelamer-carbonate","indication_name":"Renal dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renvela","generic_name":"SEVELAMER CARBONATE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Phosphate Binder","quality_score":60,"revenue":null,"mechanism":"Renvela works by binding to dietary phosphate in the gut, preventing its absorption into the bloodstream."},{"drug_id":"ergocalciferol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"temsirolimus","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Torisel","generic_name":"temsirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor","quality_score":60,"revenue":null,"mechanism":"Torisel works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"cortisone-acetate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"tyrosine-kinase-inhibitor-tki","indication_name":"Renal Cell Carcinoma (RCC)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tyrosine kinase inhibitor (TKI)","generic_name":"tyrosine-kinase-inhibitor-tki","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"TKIs","quality_score":null,"revenue":null,"mechanism":"TKIs"},{"drug_id":"cosyntropin","indication_name":"Adrenal suppression","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"COSYNTROPIN","company_name":"","drug_phase":"marketed","molecular_target":"MC2 receptor","drug_class":"Adrenocorticotropic Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"torsemide","indication_name":"Renal edema","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TORSEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/K+/2Cl- carrier system","drug_class":"Loop Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water."}],"offLabel":[],"totalMarketed":205,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT03605810","title":"Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data","phase":"","overall_status":"COMPLETED","enrollment_count":5132200,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05455528","title":"Preoperative Renal Insufficiency Predicts Postoperative Adverse Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":2421286,"lead_sponsor_name":"Taipei Medical University Hospital","has_results":false},{"nct_id":"NCT05220917","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":781430,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT02858531","title":"Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics","phase":"","overall_status":"COMPLETED","enrollment_count":760000,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT04838106","title":"Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":319600,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04764435","title":"The Effect of Physician Ownership on Dialysis Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":208213,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03225586","title":"Prospective Urban Rural Epidemiology Study","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT05050877","title":"Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention II","phase":"","overall_status":"COMPLETED","enrollment_count":184855,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT03353389","title":"Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang","phase":"","overall_status":"COMPLETED","enrollment_count":170000,"lead_sponsor_name":"Selayang Hospital","has_results":false},{"nct_id":"NCT06883318","title":"Physical, Psychological and Socioeconomic Effects of Childhood Onset Diabetes in Sweden","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":115000,"lead_sponsor_name":"Umeå University","has_results":false},{"nct_id":"NCT03575247","title":"The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":111804,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT07365111","title":"Insights Into the Continuous Renal Replacement Therapy to Critical Ill Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT06614712","title":"OPTIMISE-CKD Study_current Clinical Landscape in Spain","phase":"","overall_status":"COMPLETED","enrollment_count":91628,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04407936","title":"Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention","phase":"","overall_status":"COMPLETED","enrollment_count":88938,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT02402244","title":"Project: Every Child for Younger Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":75000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03356340","title":"The Singapore Chinese Health Study","phase":"","overall_status":"UNKNOWN","enrollment_count":63257,"lead_sponsor_name":"Duke-NUS Graduate Medical School","has_results":false},{"nct_id":"NCT06521801","title":"Cardio-Renal Registry","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04531124","title":"Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives","phase":"","overall_status":"UNKNOWN","enrollment_count":30000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT01767883","title":"Improving Evidence-Based Primary Care for Chronic Kidney Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":27000,"lead_sponsor_name":"American Academy of Family Physicians","has_results":false},{"nct_id":"NCT04682938","title":"The Prevalence and Characteristics of Adrenal Incidentaloma","phase":"","overall_status":"COMPLETED","enrollment_count":25356,"lead_sponsor_name":"Chongqing Medical University","has_results":false},{"nct_id":"NCT00960128","title":"Observational Prospective Study on Patients Treated With Norditropin®","phase":"","overall_status":"COMPLETED","enrollment_count":21249,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05568966","title":"Collection of Blood Samples for New Diagnostic Devices 2","phase":"NA","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"LumiraDx UK Limited","has_results":false},{"nct_id":"NCT05005572","title":"Treatment Choice and Outcomes for ESRD: Evidence From the First Year of a Nationwide Randomized Evaluation","phase":"NA","overall_status":"COMPLETED","enrollment_count":18621,"lead_sponsor_name":"Amy Finkelstein","has_results":false},{"nct_id":"NCT02769975","title":"Evaluation of Children With Endocrine and Metabolic-Related Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT07033117","title":"RaDIANT Health Systems Intervention","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":14000,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT04937868","title":"Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06227468","title":"A Clinical Study to Map the HLA Genomic Region in the Greek Population","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Athens LifeTech Park","has_results":false},{"nct_id":"NCT02933151","title":"Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)","phase":"NA","overall_status":"COMPLETED","enrollment_count":10457,"lead_sponsor_name":"Dialysis Clinic, Inc.","has_results":true},{"nct_id":"NCT05889806","title":"AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"Audubon Bioscience","has_results":false},{"nct_id":"NCT06176469","title":"Renal Colic and Urolithiasis in Poland","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Mikolaj Przydacz","has_results":false},{"nct_id":"NCT03988491","title":"Morbidity, Mortality, Short and Long-term Survival of Hemodialysis End-stage Kidney Disease Patients in Central Tanzania","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Benjamin Mkapa Hospital","has_results":false},{"nct_id":"NCT06413160","title":"The Cardiovascular-Renal-Metabolic (CRM) Syndrome Survey in Jordan","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Jordan Collaborating Cardiology Group","has_results":false},{"nct_id":"NCT03125265","title":"DIETary Intake, Death and Hospitalization in Adult With End-stage Kidney Disease Treated With HemoDialysis (DIET-HD) Study","phase":"","overall_status":"COMPLETED","enrollment_count":9757,"lead_sponsor_name":"Giovanni Strippoli","has_results":false},{"nct_id":"NCT05952999","title":"Analysis of the Virtual Acute Care at Home Experience","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":9654,"lead_sponsor_name":"OSF Healthcare System","has_results":false},{"nct_id":"NCT07103629","title":"Bringing Knowledge About Chronic Kidney Disease in Brazil: Filling the Gap","phase":"","overall_status":"COMPLETED","enrollment_count":8428,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06229405","title":"Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data","phase":"","overall_status":"UNKNOWN","enrollment_count":8200,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT00898365","title":"Study of Kidney Tumors in Younger Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT05168761","title":"Complications Associated With Partial Nephrectomy for Renal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":7664,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT07312929","title":"Machine Learning and Artificial Intelligence Algorithms to Optimize the Performance and Delivery of Acute Dialysis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7500,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT02019225","title":"A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration","phase":"NA","overall_status":"TERMINATED","enrollment_count":7053,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05529186","title":"Causes of Mortality in Kidney Transplant Recipients","phase":"","overall_status":"UNKNOWN","enrollment_count":7000,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT01109394","title":"Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies","phase":"","overall_status":"RECRUITING","enrollment_count":6035,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00026884","title":"Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease","phase":"","overall_status":"RECRUITING","enrollment_count":5950,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05005195","title":"Yorkshire Kidney Screening Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":5850,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT05630326","title":"Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants","phase":"","overall_status":"COMPLETED","enrollment_count":5600,"lead_sponsor_name":"Hamad Medical Corporation","has_results":false},{"nct_id":"NCT05218304","title":"Baromètre Santé Adulte 2021-2022","phase":"NA","overall_status":"SUSPENDED","enrollment_count":5471,"lead_sponsor_name":"Agence Sanitaire et Sociale de Nouvelle Calédonie","has_results":false},{"nct_id":"NCT01467466","title":"Prevention of Serious Adverse Events Following Angiography","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5177,"lead_sponsor_name":"VA Office of Research and Development","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}